• M Burt, J K Ihde, S I Hajdu, J W Smith, M S Bains, R Downey, N Martini, V W Rusch, and R J Ginsberg.
• Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
• J. Thorac. Cardiovasc. Surg. 1998 Mar 1; 115 (3): 671-80.

UnlabelledPrimary sarcomas of the mediastinum are rare, and data concerning treatment and results of therapy are sparse.ObjectiveTo assess presentation, management, prognostic factors, and survival in mediastinal sarcomas.MethodsWe reviewed our experience with 47 patients with the diagnosis of primary sarcoma of the mediastinum. Data were collected from a computerized institutional database and medical records. Survival was analyzed by Kaplan-Meier method and comparisons of survival by log rank test.ResultsThe median age of 47 patients with mediastinal sarcoma was 39 years (range 2.5 to 69 years), with a male/female ratio of 1.6. The most common complaints were chest/shoulder pain (38%) and dyspnea (23%). The most common tumor types were malignant peripheral nerve tumor (26%), spindle cell sarcoma (15%), leiomyosarcoma (9%), and liposarcoma (9%). Operation was the primary treatment modality in 72% of cases (n = 34); 22 sarcomas (47%) were completely resected. The overall 5-year survival was 32%. High-grade lesions had a significantly decreased survival (5-year survival = 27%) compared with low-grade tumors (5-year survival = 66%) (p = 0.05). The overwhelming factor determining survival was the ability to completely resect the tumors (5-year survival 49% for complete resection; 3-year survival 18% for incomplete or no resection) (p = 0.0016). Despite complete resection, local recurrence occurred in 64% of cases.ConclusionBecause the overall survival for patients with mediastinal sarcomas is 32% and the local recurrence is 64% for tumors completely resected, aggressive adjuvant therapy should continue to be systematically explored.

26 keywords...

hide…